Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience

Detalhes bibliográficos
Autor(a) principal: Pais, Fábio
Data de Publicação: 2023
Outros Autores: Aragão de Morais, José, Quintas, Ana, Soares Ferreira, Rita, Catarino, Joana, Correia, Ricardo, Bento, Rita, Garcia, Rita, Bastos Gonçalves, Frederico, Ferreira, Maria Emília
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.48750/acv.427
Resumo: INTRODUCTION: Renal cell carcinoma (RCC) frequently progress to involve the inferior vena cava (IVC) and even the right atrium (RA). Nephrectomy and eradication of the tumour thrombus, can extend survival and prevent symptoms of venous congestion. The authors evaluated the institutional experience of a tertiary center in the surgical management of RCC patients with tumour thrombi invading the IVC. METHODS: Retrospective analysis of a single-center consecutive serie of patients with RCC and IVC tumor thrombi treated with surgery in our department between 2012 and 2021 was carried out. Demographic data, diagnostic and procedural characteristics, clinical outcomes and survival analysis were examined. RESULTS: Of the included 18 patients, 33% (n=6) had smoking history, 78% (n=14) hypertension, 33% (n=6) diabetes and dyslipidaemia. Mean tumour size was 8.78±2.47cm (3-12cm), and 67% (n=12) of the cases were renal clear cell adenocarcinoma. On the basis of the Neves classification for IVC thrombus extension, 39% (n=7) of the patients had level I; 28% (n=5) level II; 17% (n=3) level III and 17% (n=3) level IV. The majority underwent radical nephrectomy, with cavotomy and vena cava thrombus removal followed by lateral venorrhaphy of the vena cava (89%,n=16). In one patient an infra-renal IVC ligation was performed and, in another patient, an IVC interposition with PTFE and a protesic-renal bypass were performed. In level IV, combined open sternotomy and cardiac bypass for RA thrombus control were necessary. Mean total operative time was 3h4min±1h19min and median intraoperative blood loss was 600ml requiring a median blood cells transfusion of 3.5units (0,16) during the hospital stay. Median ICU days was 2 days (0,14) and median hospital stay was 8 days (4,61). The mean preoperative serum creatinine was 1.23+0.38 mg/dL. After surgery, there was a mean decrease of serum creatinine of 0.001 mg/dL (p=.991) (paired T test), confirming the absence of renal impairment. Only one patient required reintervention in the post-operative course for splenectomy. Post- operative complications included one case of pulmonary embolism, pneumonia, acute coronary syndrome and two cases of temporary acute renal lesion. There was no 30-day mortality. Five patients underwent adjuvant chemotherapy. Median follow-up time was 19.5 months (6-46.2 months). The four-year overall survival rate was of 52.4% (figure 1). CONCLUSION: For advanced RCC with tumour thrombus extension into the IVC, despite the expected poor prognosis, nephrectomy and eradication of the entire tumour thrombus, has low morbidity and can prolong patient survival, in line with the presented results.
id RCAP_ced5ed803a771adf91a66a9dd7d3287f
oai_identifier_str oai:ojs.acvjournal.com:article/427
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experienceRenal cell carcinomaInferior vena cavaVenous thrombectomyOncovascular surgeryINTRODUCTION: Renal cell carcinoma (RCC) frequently progress to involve the inferior vena cava (IVC) and even the right atrium (RA). Nephrectomy and eradication of the tumour thrombus, can extend survival and prevent symptoms of venous congestion. The authors evaluated the institutional experience of a tertiary center in the surgical management of RCC patients with tumour thrombi invading the IVC. METHODS: Retrospective analysis of a single-center consecutive serie of patients with RCC and IVC tumor thrombi treated with surgery in our department between 2012 and 2021 was carried out. Demographic data, diagnostic and procedural characteristics, clinical outcomes and survival analysis were examined. RESULTS: Of the included 18 patients, 33% (n=6) had smoking history, 78% (n=14) hypertension, 33% (n=6) diabetes and dyslipidaemia. Mean tumour size was 8.78±2.47cm (3-12cm), and 67% (n=12) of the cases were renal clear cell adenocarcinoma. On the basis of the Neves classification for IVC thrombus extension, 39% (n=7) of the patients had level I; 28% (n=5) level II; 17% (n=3) level III and 17% (n=3) level IV. The majority underwent radical nephrectomy, with cavotomy and vena cava thrombus removal followed by lateral venorrhaphy of the vena cava (89%,n=16). In one patient an infra-renal IVC ligation was performed and, in another patient, an IVC interposition with PTFE and a protesic-renal bypass were performed. In level IV, combined open sternotomy and cardiac bypass for RA thrombus control were necessary. Mean total operative time was 3h4min±1h19min and median intraoperative blood loss was 600ml requiring a median blood cells transfusion of 3.5units (0,16) during the hospital stay. Median ICU days was 2 days (0,14) and median hospital stay was 8 days (4,61). The mean preoperative serum creatinine was 1.23+0.38 mg/dL. After surgery, there was a mean decrease of serum creatinine of 0.001 mg/dL (p=.991) (paired T test), confirming the absence of renal impairment. Only one patient required reintervention in the post-operative course for splenectomy. Post- operative complications included one case of pulmonary embolism, pneumonia, acute coronary syndrome and two cases of temporary acute renal lesion. There was no 30-day mortality. Five patients underwent adjuvant chemotherapy. Median follow-up time was 19.5 months (6-46.2 months). The four-year overall survival rate was of 52.4% (figure 1). CONCLUSION: For advanced RCC with tumour thrombus extension into the IVC, despite the expected poor prognosis, nephrectomy and eradication of the entire tumour thrombus, has low morbidity and can prolong patient survival, in line with the presented results.Sociedade Portuguesa de Angiologia e Cirurgia Vascular2023-01-07info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.48750/acv.427https://doi.org/10.48750/acv.427Angiologia e Cirurgia Vascular; Vol. 18 No. 3 (2022): September; 172-175Angiologia e Cirurgia Vascular; Vol. 18 N.º 3 (2022): September; 172-1752183-00961646-706Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://acvjournal.com/index.php/acv/article/view/427http://acvjournal.com/index.php/acv/article/view/427/302Copyright (c) 2022 Angiologia e Cirurgia Vascularinfo:eu-repo/semantics/openAccessPais, FábioAragão de Morais, JoséQuintas, AnaSoares Ferreira, RitaCatarino, JoanaCorreia, RicardoBento, RitaGarcia, RitaBastos Gonçalves, FredericoFerreira, Maria Emília2023-01-11T10:18:34Zoai:ojs.acvjournal.com:article/427Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:30:07.319829Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience
title Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience
spellingShingle Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience
Pais, Fábio
Renal cell carcinoma
Inferior vena cava
Venous thrombectomy
Oncovascular surgery
title_short Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience
title_full Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience
title_fullStr Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience
title_full_unstemmed Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience
title_sort Clinical outcomes after vena cava thrombectomy for renal cell carcinoma with venous extension – institutional experience
author Pais, Fábio
author_facet Pais, Fábio
Aragão de Morais, José
Quintas, Ana
Soares Ferreira, Rita
Catarino, Joana
Correia, Ricardo
Bento, Rita
Garcia, Rita
Bastos Gonçalves, Frederico
Ferreira, Maria Emília
author_role author
author2 Aragão de Morais, José
Quintas, Ana
Soares Ferreira, Rita
Catarino, Joana
Correia, Ricardo
Bento, Rita
Garcia, Rita
Bastos Gonçalves, Frederico
Ferreira, Maria Emília
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pais, Fábio
Aragão de Morais, José
Quintas, Ana
Soares Ferreira, Rita
Catarino, Joana
Correia, Ricardo
Bento, Rita
Garcia, Rita
Bastos Gonçalves, Frederico
Ferreira, Maria Emília
dc.subject.por.fl_str_mv Renal cell carcinoma
Inferior vena cava
Venous thrombectomy
Oncovascular surgery
topic Renal cell carcinoma
Inferior vena cava
Venous thrombectomy
Oncovascular surgery
description INTRODUCTION: Renal cell carcinoma (RCC) frequently progress to involve the inferior vena cava (IVC) and even the right atrium (RA). Nephrectomy and eradication of the tumour thrombus, can extend survival and prevent symptoms of venous congestion. The authors evaluated the institutional experience of a tertiary center in the surgical management of RCC patients with tumour thrombi invading the IVC. METHODS: Retrospective analysis of a single-center consecutive serie of patients with RCC and IVC tumor thrombi treated with surgery in our department between 2012 and 2021 was carried out. Demographic data, diagnostic and procedural characteristics, clinical outcomes and survival analysis were examined. RESULTS: Of the included 18 patients, 33% (n=6) had smoking history, 78% (n=14) hypertension, 33% (n=6) diabetes and dyslipidaemia. Mean tumour size was 8.78±2.47cm (3-12cm), and 67% (n=12) of the cases were renal clear cell adenocarcinoma. On the basis of the Neves classification for IVC thrombus extension, 39% (n=7) of the patients had level I; 28% (n=5) level II; 17% (n=3) level III and 17% (n=3) level IV. The majority underwent radical nephrectomy, with cavotomy and vena cava thrombus removal followed by lateral venorrhaphy of the vena cava (89%,n=16). In one patient an infra-renal IVC ligation was performed and, in another patient, an IVC interposition with PTFE and a protesic-renal bypass were performed. In level IV, combined open sternotomy and cardiac bypass for RA thrombus control were necessary. Mean total operative time was 3h4min±1h19min and median intraoperative blood loss was 600ml requiring a median blood cells transfusion of 3.5units (0,16) during the hospital stay. Median ICU days was 2 days (0,14) and median hospital stay was 8 days (4,61). The mean preoperative serum creatinine was 1.23+0.38 mg/dL. After surgery, there was a mean decrease of serum creatinine of 0.001 mg/dL (p=.991) (paired T test), confirming the absence of renal impairment. Only one patient required reintervention in the post-operative course for splenectomy. Post- operative complications included one case of pulmonary embolism, pneumonia, acute coronary syndrome and two cases of temporary acute renal lesion. There was no 30-day mortality. Five patients underwent adjuvant chemotherapy. Median follow-up time was 19.5 months (6-46.2 months). The four-year overall survival rate was of 52.4% (figure 1). CONCLUSION: For advanced RCC with tumour thrombus extension into the IVC, despite the expected poor prognosis, nephrectomy and eradication of the entire tumour thrombus, has low morbidity and can prolong patient survival, in line with the presented results.
publishDate 2023
dc.date.none.fl_str_mv 2023-01-07
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.48750/acv.427
https://doi.org/10.48750/acv.427
url https://doi.org/10.48750/acv.427
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://acvjournal.com/index.php/acv/article/view/427
http://acvjournal.com/index.php/acv/article/view/427/302
dc.rights.driver.fl_str_mv Copyright (c) 2022 Angiologia e Cirurgia Vascular
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Angiologia e Cirurgia Vascular
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Angiologia e Cirurgia Vascular
publisher.none.fl_str_mv Sociedade Portuguesa de Angiologia e Cirurgia Vascular
dc.source.none.fl_str_mv Angiologia e Cirurgia Vascular; Vol. 18 No. 3 (2022): September; 172-175
Angiologia e Cirurgia Vascular; Vol. 18 N.º 3 (2022): September; 172-175
2183-0096
1646-706X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130758256787457